A Difficult Case of Calcineurin Inhibitor Neurotoxicity Post-Haploidentical HCT With a Successful Novel Solution: Cytotoxic T-Lymphocyte-Associated Protein 4-Immunoglobulin Blockade for GVHD Prophylaxis
Cell Transplantation · 2024
DOI: 10.1177/09636897241265249 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cell Transplantation, 2024. Verfasst von Kaitlyn Dykes und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology Oncology, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Calcineurin Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Post–allogeneic hematopoietic cell transplant (HCT) immunosuppression regimens are given as graft-versus-host disease (GVHD) prophylaxis. Most GVHD prophylaxis regimens are based on calcineurin inhibitors (CNIs). Unfortunately, CNIs are associated with significant associated morbidity, frequently cannot be tolerated, and often need to be discontinued. There is no consensus as to which alternative immunosuppression should be used in cases where CNIs have to be permanently discontinued. Cytotoxic T-lymphocyte-associated protein 4-immunoglobulin (CTLA4-Ig) blocking agents are well tolerated and have been used extensively in patients with autoimmune disease and as post-transplant immunosuppression. There are two CTLA4-Ig agents: belatacept and abatacept. Belatacept is routinely used in adult kidney transplantation to prevent rejection and abatacept has been approved by the Food and Drug Administration (FDA) for GVHD prophylaxis in patients undergoing a matched or one allele-mismatched unrelated allogenic HCT. Herein, we describe a case in which abatacept was given off-label to replace tacrolimus GVHD prophylaxis in a patient with neurotoxicity undergoing haploidentical HCT. This case suggests that CTLA4-Ig blockade may be a good alternative to a CNI in cases where the CNI needs to be discontinued and warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology Oncology, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
- Division of Blood & Bone Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
ORCID-Profile: Kaitlyn Dykes
Zitieren
APA
Dykes, K., Tzachanis, D., & Koura, D. (2024). A Difficult Case of Calcineurin Inhibitor Neurotoxicity Post-Haploidentical HCT With a Successful Novel Solution: Cytotoxic T-Lymphocyte-Associated Protein 4-Immunoglobulin Blockade for GVHD Prophylaxis. Cell Transplantation. https://doi.org/10.1177/09636897241265249
Vancouver
Dykes K, Tzachanis D, Koura D. A Difficult Case of Calcineurin Inhibitor Neurotoxicity Post-Haploidentical HCT With a Successful Novel Solution: Cytotoxic T-Lymphocyte-Associated Protein 4-Immunoglobulin Blockade for GVHD Prophylaxis. Cell Transplantation. 2024. doi:10.1177/09636897241265249
BibTeX
@article{Dykes2024,
author = {Dykes, Kaitlyn and Tzachanis, Dimitrios and Koura, Divya},
title = {A Difficult Case of Calcineurin Inhibitor Neurotoxicity Post-Haploidentical HCT With a Successful Novel Solution: Cytotoxic T-Lymphocyte-Associated Protein 4-Immunoglobulin Blockade for GVHD Prophylaxis},
journal = {Cell Transplantation},
year = {2024},
doi = {10.1177/09636897241265249}
}
EUVIMED